Finox Biotech AG

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – June 8, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today published the invitation to its 2023 Annual General Meeting of Shareholders to be held on June 29, 2023, at 10:30 CEST at the company's offices in Geneva, Chemin des Aulx 12, 3rd floor, 1228 Plan-les-Ouates, Switzerland. The agenda of the meeting will be as follows: 1 Approval of the Management Report, the Statutory Financial Statements and the Consolidated Financial Statements for Fiscal Year 2022 The Board of Directors proposes that the management report, the statutory financial statements and the consolidated financial statements of ObsEva SA for fiscal year 2022 be approved. 2 Discharge of Liability for the Members of the Board of Directors and of the Executive Committee The Board of Directors proposes that shareholders release the members of the Board of Directors and of the Executive Committee from liability for their activities during fiscal year 2022. 3 Appropriation of Financial Results The Board of Directors proposes that the loss of USD 36,373,527 for the financial year 2022 be appropriated as follows: Fnancial Year 2022Accumulated losses brought forward from previous yearUSD 383,931,623Net loss for the year 2022USD 36,373,527Accumulated losses to be carried forwardUSD 420,305,150 4 Elections to the Board of Directors and Election of the Chairman of the Board of Directors The Board of Directors proposes the election, respectively re-election, of the following nominees for a term of one year expiring at the closing of the 2024 Annual General Meeting: 4.1 Re-election of Ernest Loumaye as member of the Board of Directors and election as Chairman of the Board of Directors 4.2 Re-election of Catarina Edfjäll as member of the Board of Directors 4.3 Election of Luigi Marro as member of the Board of Directors Luigi Marro served as Chief Transformation Officer of ObsEva from October 2021 to February 2023. Mr. Marro is a pharmaceutical and biotech executive with over 20 years of experience. He has a background in finance and operations and has managed global businesses across multiple therapeutic areas from development stages through commercialization. Prior to joining ObsEva, Mr. Marro founded in February 2019 his own consulting company, Martan Market GmbH, to support biotech and pharma startups. From May 2014 to February 2019, he served as Chief Financial Officer at Finox Biotech, which launched the first biosimilar recombinant follicle stimulating hormone (r-FSH) product to market. From November 2012 to July 2013, Luigi held leadership positions at Voisin Life Sciences Consulting SA as Chief Operating Officer. He also acted as Senior Director Strategy Development and Business Performance at Merck Serono from January 2010 to October 2012. Mr. Marro also held elevating strategic roles at Serono, prior to its acquisition by Merck. Mr. Marro holds a university degree in Demographic and Economical Statistic Sciences from La Sapienza in Rome as well as a Master of Business Administration from Luiss Management school in Rome. 4.4 Election of Fabien de Ladonchamps as member of the Board of Directors Fabien de Ladonchamps is a biotech executive with 25 years of experience in finance and administrative roles, primarily with Swiss biotech companies. Mr. de Ladonchamps has been appointed Chief Executive Officer of ObsEva in May 2023. Prior to that, he was a member of ObsEva’s Executive Committee from October 2013 to July 2022, during which he had held the roles of Chief Administrative Officer and Interim Chief Financial Officer. He also served as the sole finance and accounting officer for the Company for a total of four years during which over $110 Million in equity proceeds were raised through private and public financing rounds. Mr. de Ladonchamps was instrumental in the Company’s listings on both Nasdaq in 2017 and the Swiss Exchange in 2018. Prior to joining ObsEva, Mr. de Ladonchamps held a variety of management roles at Addex Therapeutics, from 2008 to 2013. Mr. de Ladonchamps holds a degree in Finance and Accounting from the Lyon III University in Lyon, France. 5 Elections to the Compensation Committee The Board of Directors proposes the election, respectively re-election, of the following nominees for a term of one year expiring at the closing of the 2024 Annual General Meeting: 5.1 Re-election of Catarina Edfjäll as member of the Compensation Committee 5.2 Election of Ernest Loumaye as member of the Compensation Committee 6 Re-election of PricewaterhouseCoopers SA as ObsEva SA's Auditors The Board of Directors proposes the re-election of PricewaterhouseCoopers SA as ObsEva SA's auditors for the fiscal year 2023. 7 Re-election of Perréard de Boccard SA as Independent Representative The Board of Directors proposes the re-election of Perréard de Boccard SA, Rue de la Coulouvrenière 29, 1204 Genève, as Independent Representative of shareholders for a one-year term expiring at the closing of the 2024 Annual General Meeting. 8 Compensation of the Board of Directors and the Executive Committee 8.1 Consultative vote on the Compensation Report 2022 The Board of Directors proposes that the compensation report 2022 be accepted (consultative vote). 8.2 Approval of the Compensation of the Board of Directors The Board of Directors proposes that the shareholders approve a maximum aggregate amount of compensation of CHF 1,250,000 for the members of the Board of Directors for the period from the 2023 Annual General Meeting to the 2024 Annual General Meeting. 8.3 Approval of the Compensation of the Executive Committee for the Fiscal Year 2024 The Board of Directors proposes that the shareholders approve a maximum aggregate amount of compensation of CHF 1,500,000 for the members of the Executive Committee for the fiscal year 2024. 9 Introduction of a Capital Band and Related Amendments to the Articles of Association The Board of Directors proposes to delete the current Article 5a relating to the authorized capital and to introduce a new Article 5a relating to a capital band of 72,933,302 fully paid-in registered shares with a par value of CHF 1/13 of a franc each, ranging from CHF 11,220,508 and 1/13 of a franc (lower limit) to CHF 16,830,762 and 1/13 of a franc (upper limit), so that the Board of Directors be authorized to increase ObsEva SA's share capital within the capital band, at once or in several times, until 29 June 2028, unless the capital band lapses at an earlier date, and to amend the Articles of Association accordingly. 10 Increase of ObsEva SA's Conditional Share Capital for Financing Purposes The Board of Directors proposes to increase by 35,869,210, corresponding to an increase from 18,598,619 to 54,467,829, the number of new ordinary shares that can be issued upon exercise of option and conversion rights that may be granted in connection with bonds, similar debt instruments, loans or other financial market instruments or contractual obligations of the Company or one of its subsidiaries, and/or upon exercise of option rights issued by the Company or one of its subsidiaries, and to amend the Articles of Association accordingly. The full invitation to the AGM 2023 may be found in the general meetings section of the Company's website, [here]. To access the invitation to the AGM 2023 directly, please click [here]. About ObsEva ObsEva is a biopharmaceutical company developing novel therapies to improve women’s reproductive health and pregnancy. ObsEva has established a development program focused on improving in vitro fertilization success rates. ObsEva is listed on the SIX Swiss Exchange where it is traded under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com. For further information, please contact: For general information:contact@obseva.ch For investors information:IR@obseva.ch ObsEva SAChemin des Aulx 12,1228 Plan-les-OuatesSwitzerland +41 22 552 1550 Attachment 2023.06.08 - Press Release AGM invitation

DUBLIN, Oct. 24, 2022 /PRNewswire/ -- The "Male Hypogonadism Market By Drug Delivery, By Therapy, By Type: Global Opportunity Analysis and Industry Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering. The global male hypogonadism market was valued $ 3,072.86 million in 2020 and expected to reach $ 5,085.03 million by 2030, with a CAGR of 5.1% from 2021 to 2030. Hypogonadism is characterized as lack of testosterone level or lack of spermatozoa production, or both. It is caused owing to the disorder related to the testes (primary hypogonadism) or the hypothalamic-pituitary axis (secondary hypogonadism). Both can be inherited or acquired, due to ageing, hormonal disorders or medicines. In addition, various congenital enzyme abnormalities result in various degrees of androgen resistance in target organs. Hormone levels corroborate the diagnosis. The treatment for gonadotropin-releasing hormone, gonadotropin, or testosterone replacement differs depending on the aetiology. The factors that drive the global male hypogonadism market are increase in cases of hypogonadism, surge in awareness of hypogonadism, and rise in number of treatment options. In addition, hypogonadism is prevalent in the geriatric population as well as in patients with diabetes and obesity. As a result, increase in population and rise in the incidence and prevalence of chronic disorders, such as diabetes and obesity drive the growth of the market. According to clinical research, testosterone levels in males aged 60-80 years are 20 percent and 80 percent lower, respectively, than testosterone levels in young men. Hypogonadism is most common in men aged above 60. In countries like Japan, China, and the U.S. there is surge in demand for male hypogonadism treatments, owing to increase in geriatric population and surge in infertility rates. The male hypogonadism market is segmented on the basis of therapy, drug delivery, type, and region. Depending on therapy, it is divided into testosterone replacement therapy and gonadotropin & gonadotropin-releasing hormones therapy. The gonadotropin-releasing hormones therapy segment is segmented into luteinizing hormone (LH), follicle-stimulating hormone (FSH), human chorionic gonadotropin (HCG), and gonadotropin-releasing hormone (GNRH). According to drug delivery, it is fragmented into topical gels, injectable, transdermal patches, and others. As per the type, it is classified into Klinefelter's syndrome, Kallmann syndrome, pituitary disorders, and others. Region wise, it is analyzed across North America, Europe, Asia Pacific, and LAMEA. Major key players operating in the global male hypogonadism market are Allergan PLC., Bayer AG, Eli Lily & Company, Endo Iternational PLC., Ferring Holdings SA, Finox Biotech, Merck & Co. Inc., Pfizer, Perrigo Company PLC., Teva Pharmaceutical Industries Ltd. Key Benefits For Stakeholders This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the male hypogonadism market analysis from 2020 to 2030 to identify the prevailing male hypogonadism market opportunities. The market research is offered along with information related to key drivers, restraints, and opportunities. Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network. In-depth analysis of the male hypogonadism market segmentation assists to determine the prevailing market opportunities. Major countries in each region are mapped according to their revenue contribution to the global market. Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players. The report includes the analysis of the regional as well as global male hypogonadism market trends, key players, market segments, application areas, and market growth strategies. Key Topics Covered: CHAPTER 1: INTRODUCTION CHAPTER 2: EXECUTIVE SUMMARY CHAPTER 3: MARKET OVERVIEW 3.1. Market definition and scope 3.2. Key findings 3.2.1. Top investment pockets 3.3. Porter's five forces analysis 3.4. Top player positioning 3.5. Market dynamics 3.5.1. Drivers 3.5.2. Restraints 3.5.3. Opportunities 3.6. COVID-19 Impact Analysis on the market CHAPTER 4: MALE HYPOGONADISM MARKET, BY DRUG DELIVERY 4.1 Overview 4.1.1 Market size and forecast 4.2 Topical Gels 4.2.1 Key market trends, growth factors and opportunities 4.2.2 Market size and forecast, by region 4.2.3 Market analysis by country 4.3 Injectables 4.3.1 Key market trends, growth factors and opportunities 4.3.2 Market size and forecast, by region 4.3.3 Market analysis by country 4.4 Transdermal Patches 4.4.1 Key market trends, growth factors and opportunities 4.4.2 Market size and forecast, by region 4.4.3 Market analysis by country 4.5 Others 4.5.1 Key market trends, growth factors and opportunities 4.5.2 Market size and forecast, by region 4.5.3 Market analysis by country CHAPTER 5: MALE HYPOGONADISM MARKET, BY THERAPY 5.1 Overview 5.1.1 Market size and forecast 5.2 Testosterone Replacement Therapy 5.2.1 Key market trends, growth factors and opportunities 5.2.2 Market size and forecast, by region 5.2.3 Market analysis by country 5.3 Gonadotropin and Gonadotropin Releasing Hormone Therapy 5.3.1 Key market trends, growth factors and opportunities 5.3.2 Market size and forecast, by region 5.3.3 Market analysis by country CHAPTER 6: MALE HYPOGONADISM MARKET, BY TYPE 6.1 Overview 6.1.1 Market size and forecast 6.2 Klinefelters Syndrome 6.2.1 Key market trends, growth factors and opportunities 6.2.2 Market size and forecast, by region 6.2.3 Market analysis by country 6.3 Kallmann Syndrome 6.3.1 Key market trends, growth factors and opportunities 6.3.2 Market size and forecast, by region 6.3.3 Market analysis by country 6.4 Pituitary Disorders 6.4.1 Key market trends, growth factors and opportunities 6.4.2 Market size and forecast, by region 6.4.3 Market analysis by country 6.5 Others 6.5.1 Key market trends, growth factors and opportunities 6.5.2 Market size and forecast, by region 6.5.3 Market analysis by country CHAPTER 7: MALE HYPOGONADISM MARKET, BY REGION CHAPTER 8: COMPANY LANDSCAPE 8.1. Introduction 8.2. Top winning strategies 8.3. Product Mapping of Top 10 Player 8.4. Competitive Dashboard 8.5. Competitive Heatmap 8.6. Key developments CHAPTER 9: COMPANY PROFILES 9.1 Allergan plc 9.1.1 Company overview 9.1.2 Company snapshot 9.1.3 Operating business segments 9.1.4 Product portfolio 9.1.5 Business performance 9.1.6 Key strategic moves and developments 9.2 Pfizer Inc. 9.2.1 Company overview 9.2.2 Company snapshot 9.2.3 Operating business segments 9.2.4 Product portfolio 9.2.5 Business performance 9.2.6 Key strategic moves and developments 9.3 Bayer AG 9.3.1 Company overview 9.3.2 Company snapshot 9.3.3 Operating business segments 9.3.4 Product portfolio 9.3.5 Business performance 9.3.6 Key strategic moves and developments 9.4 Eli Lilly and Company Ltd. 9.4.1 Company overview 9.4.2 Company snapshot 9.4.3 Operating business segments 9.4.4 Product portfolio 9.4.5 Business performance 9.4.6 Key strategic moves and developments 9.5 Endo International plc. 9.5.1 Company overview 9.5.2 Company snapshot 9.5.3 Operating business segments 9.5.4 Product portfolio 9.5.5 Business performance 9.5.6 Key strategic moves and developments 9.6 Merck & Co., Inc. 9.6.1 Company overview 9.6.2 Company snapshot 9.6.3 Operating business segments 9.6.4 Product portfolio 9.6.5 Business performance 9.6.6 Key strategic moves and developments 9.7 Ferring 9.7.1 Company overview 9.7.2 Company snapshot 9.7.3 Operating business segments 9.7.4 Product portfolio 9.7.5 Business performance 9.7.6 Key strategic moves and developments 9.8 Finox Biotec 9.8.1 Company overview 9.8.2 Company snapshot 9.8.3 Operating business segments 9.8.4 Product portfolio 9.8.5 Business performance 9.8.6 Key strategic moves and developments 9.9 Teva Pharmaceutical Industries Ltd. 9.9.1 Company overview 9.9.2 Company snapshot 9.9.3 Operating business segments 9.9.4 Product portfolio 9.9.5 Business performance 9.9.6 Key strategic moves and developments 9.10 Perrigo Company plc 9.10.1 Company overview 9.10.2 Company snapshot 9.10.3 Operating business segments 9.10.4 Product portfolio 9.10.5 Business performance 9.10.6 Key strategic moves and developments For more information about this report visit Logo - Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 SOURCE Research and Markets

Hypogonadism in males refers to a condition in the male body where the testes show a significantly reduced level of functioning than normal. The overall result of male hypogonadism is a reduction in the rate of biosynthesis of male sex hormones. This state is more commonly known as interrupted stage 1 puberty. Hypoandrogenism, or the low androgen or testosterone level in a male can vary in severity from person to person. It is often the cause of partial or complete infertility. There are multiple forms of male hypogonadism and even more ways to classify them. Most endocrinologists commonly classify male hypogonadism on the basis of the level of defectiveness of the male reproductive system. In many cases, doctors also measure the level of gonadotropins to classify a patient between primary and secondary male hypogonadism. Primary male hypogonadism refers to the cause of the condition being due to defective gonads. There are different types of primary male hypogonadism, including Turner syndrome and Klinefelter syndrome. Secondary male hypogonadism is caused by defects in pituitary or hypothalamic glands. They include Kallmann syndrome and hypopituitarism. Global Male Hypogonadism Market: Overview Male Hypogonadism refers to a clinical condition, wherein the testes fail to produce enough testosterone leading to delayed puberty or incomplete development. The condition is related to impaired development of muscle mass, development of breast tissues, impaired body hair growth, and lack of deepening of the voice. The male Hypogonadism market can be segmented by therapy, type, drug delivery, and geography. The report presents an in-depth analysis of the global male hypogonadism market with current trends and future estimates to explain the imminent investment pockets. The quantitative analysis of the market for the forecast period from 2017 to 2025 will enable stakeholders to capitalize on the prevailing growth opportunities. GET BROCHURE OF THE REPORT Global Male Hypogonadism Market: Trends and Opportunities The top driver of the male hypogonadism market includes rising prevalence of testosterone deficiency among men, increasing infertility rates, and increasing awareness among individuals about hypogonadism treatment due to awareness drives organized by several governments across the world. Moreover, high risk of hypogonadism among the geriatric population with obesity and diabetes, and increasing prevalence of chronic disorders among the geriatrics are further expected to boost the market’s growth. However, factors such as high side effects of testosterone products are challenging the growth of testosterone replacement therapy market. Top players in the market are focused on research and development to introduce newer products with fewer or negligible side effects and improved results. For example, LPCN 1111, a product which is under development from Lipocine Inc., is a newer testosterone prodrug that utilizes Lip’ral technology for enhanced systemic absorption and for enhanced solubility of testosterone. Nevertheless, technological advancements are anticipated to extend new opportunities to the market’s growth. GET TABLE OF CONTENT OF THE REPORT Global Male Hypogonadism Market: Regional Overview The global male Hypogonadism market can be analyzed with respect to the regional segments of North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa. North America held the majority share of the global market in the recent past and is expected to retain its dominant position in the near future. This is mainly due to the rise in the number of individuals suffering from primary and secondary conditions of hypogonadism, and rising awareness among individuals about treatment options for the condition. Moreover, the presence of ultra-modern healthcare infrastructure and increasing popularity of technologically advanced products are expected to offer new opportunities for top players in this market. The region is closely followed by Europe. Asia Pacific is expected to offer lucrative opportunities to this market due to the modernization of the healthcare infrastructure in the emerging economies of India and China and the increasing awareness about the treatment for the condition. In Asia Pacific, the increasing prevalence of hypogonadism and infertility rates along with the rising geriatric population base with diabetes and obesity are propelling the growth of this market. China, Taiwan, and Malaysia are some of the countries that display the highest rate of male hypogonadism. Major Companies Mentioned in Report Some of the key players in the male Hypogonadism market include AbbVie Inc., Astrazeneca plc, Eli Lilly and Company Ltd., Merck & Co. Inc., SA, Finox Biotech, Laboratories Genevrier, Teva Pharmaceutical Industries Ltd., Allergan plc, Bayer AG, Endo International plc, IBSA Institut Biochimque, and Ferring. Key players are focused on product approval for growth considerations and to cater to the changing demand of the industry. The introduction of innovative and technologically advanced products is also the focus of key players to increase their market share and for serving patients in a better manner. GET DISCOUNT ON THE LATEST REPORT TMR Research has rich experience in developing state-of-the-art reports for a wide array of markets and sectors. The brilliance of the experts at TMR Research and their alacrity to conduct thorough research and create phenomenal reports makes TMR Research better than others. 5-Point Growth Formula The 5-point growth formula developed by TMR Research provides an insight to the stakeholders and CXOs about the current situation in the market. The growth formula makes the report a perfect companion for the stakeholders and CXOs. The 5-point growth formula includes the following points: Current and Future Threats Accurate Trend Analysis Regional Assessment Industrial Analogy COVID-19 Impact Current and Future Threats Along with studying the opportunities necessary for growth, threats are also an important aspect to look upon for the companies and stakeholders in a specific sector. TMR Research studies every negative aspect that will hinder the growth of a specific area of business and includes it in the report. The stakeholders and CXOs will have the benefit of assessing the threat and take the necessary steps to prevent the hindrance caused due to the threats. Accurate Trend Analysis Keeping up with the latest trends is crucial in any business or sector. While stakeholders are aware of the trends that are on the surface, TMR Researchers find trends that are deeply entrenched in the particular market or sector. The reports are constantly updated with the latest trends so that the stakeholders and CXOs can derive benefits from the trends and generate good revenues. Regional Assessment Demography forms an important part of the growth pattern of all the markets. Diving deep into the demographics enables maximum output from specific areas. The TMR Research team assesses every region and picks out the vital points that have a large impact on the growth of a market. Industrial Analogy The analysts at TMR Research conduct an all-round analysis on the competitive landscape of the market. The observations recorded by the analysts are added to the reports so that every stakeholder gets a glimpse of the competitive scenario and frame their business plans according to the situation. COVID-19 Impact The COVID-19 outbreak has changed the growth projections of numerous sectors and businesses. The analysts at TMR Research have conducted a conscientious survey on the markets after the pandemic struck. The analysts have put forth their brilliant and well-researched opinions in the report. The opinions will help the stakeholders to plan their strategy accordingly. The reports offer answers to the top 7 questions that revolve around the growth of the market What are the diverse growth parameters influencing the market? Which regions will contribute largely to the growth of the market What are the recent innovations and technological advancements in the market? What are the emerging trends across the market? How has COVID-19 affected the market? What will be the post-pandemic scenario of the market? What are the major threats that will dent the growth prospects of the market? About TMR Research TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends. Contact: Rohit Bhisey TMR Research, 3739 Balboa St # 1097, San Francisco, CA 94121 United States Tel: +1-415-520-1050 Visit Site: